SPONTANEOUS SEROREVERSION OF ANTI-HEPATITIS C VIRUS DURING THE NATURAL COURSE OF HEPATITIS C VIRUS INFECTION IN THE PATIENTS EVALUATED FOR TREATMENT.

Slides:



Advertisements
Similar presentations
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Access to HCV triple therapy with Telaprevir or Boceprevir in a real-life setting in HIV-HCV.
Advertisements

Liver Disease and Thalassaemia George Constantinou.
IMPACT OF ORGAN AND NON-ORGAN-SPECIFIC AUTOANTIBODIES ON THE TREATMENT OUTCOME OF PATIENTS WITH HEPATITIS D VIRUS INFECTION 1 Department of Gastroenterology,
Management of Chronic HCV Infection by PMDs Rod Rahimi Osler Journal Club
Institute Institute of Cardiovascular Diseases Prof Dr George IM Georgescu, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania WC. Hsieh,
HEPATITIS C VIRUS REINFECTION IN PEOPLE WHO INJECT DRUG (PWID) PREVIOUSLY SUCCESFULY TREATED G. Ntetskas, V. Papastergiou, L. Skorda, A. Katsili, E. Anastasiou,
EPIDEMIOLOGICAL AND CLINICAL FEATURES OF LIVER CIRRHOSIS
HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
Hepatitis C: Overview and Epidemiology
129 patients with chronic hepatitis C
Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.
Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study
Estimates of People with Hepatitis C in Wyoming
Estimates of People with Hepatitis C in Virginia
Hepatitis and Liver Diseases
*Dr. Mushtak T. S Al-Ouqaili **Dr. Yasin Hamad Majeed
THE APPROPRIATENESS OF PPI PRESCRIPTION IN A GENERAL MEDICAL COHORT
BACKGROUND MATERIALS & METHODS RESULTS CONCLUSIONS
Hepatitis C Incidence and Prevalence in the U.S.
Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
Correlation between Duration of Viral Infection and Extrahepatic Manifestations in Patients with Chronic Hepatitis C Virus Infection Sinziana Daia1, Anca.
Estimates of People with Hepatitis C in Mississippi
Estimates of People with Hepatitis C in Illinois
Estimates of People with Hepatitis C in Connecticut
DOES HIV/ HEPATITIS COINFECTION AFFECT PEOPLE ACCESSING CARE FOR HIV
R. Cavallo  Clinical Microbiology and Infection 
Achieving WHO Recommendations for HCV Elimination in the Western Pacific Region L. Wei April 13, 2016.
Estimates of People with Hepatitis C in Virginia
Arpan Mohanty, Sebhat Erqou, Kathleen A
Volume 140, Issue 2, Pages e1 (February 2011)
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
Estimates of People with Hepatitis C in Massachusetts
Estimates of People with Hepatitis C in Maine
A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus  Amit G. Singal, Michael.
Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C  Chi–Jen Chu, Munira Hussain,
A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir Prof.dr.Abdel fattah hanno Dr. Doaa al wazzan.
Volume 73, Pages S53-S68 (April 2008)
Volume 155, Issue 5, Pages e2 (November 2018)
Jean-Michel Pawlotsky  Gastroenterology 
Estimates of People with Hepatitis C in Kansas
Division of Viral Hepatitis, CDC
2018 Postgraduate Research Symposium: Exploring opportunities
No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening  Brianna L. Norton,
Estimates of People with Hepatitis C in Alabama
Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H
Managing Age-Related Clinical Issues in Hemophilia
Acute hepatitis C: Current status and remaining challenges
A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China  Y. Zhang,
Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection  Ira M. Jacobson, Gary L. Davis, Hashem El–Serag, Francesco.
HCV epidemiology in high-risk groups and the risk of reinfection
Volume 132, Issue 1, Pages 5-6 (January 2007)
Estimates of People with Hepatitis C in Nebraska
Estimates of People with Hepatitis C in Arkansas
Estimates of People with Hepatitis C in Wisconsin
Alessio Aghemo, Maria Francesca Donato  Gastroenterology 
Hepatitis C treatment in patients with kidney disease
Christos Konstantakis, Maria Karamesini, Christos Triantos 
Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality From Liver Cancer in the United States  Zobair M. Younossi, Maria Stepanova 
Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection  Harald Farnik, Christian M. Lange,
Novel Therapies for Hepatitis C Virus Based on Lessons From Virology
Clinical Gastroenterology and Hepatology
Interferon free treatment
Robert G. Gish, Nezam H. Afdhal, Douglas T. Dieterich, K
Kathleen E. Corey, Andrew S
The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.
E-POSTER Nr 5 THE RISK OF VARICEAL BLEEDING AFTER STOPPING BETA BLOCKERS IN CIRRHOTIC PATIENTS WITH REFRACTORY ASCITES Irina Girleanu, Anca Trifan, Andreea.
Pei-Yuan Su,Yu-Chun Hsu,Shun-Sheng Wu,Wei-Wen Su,Maw-Soan Soon
METABOLIC CHANGES AFTER VIRAL ERADICATION IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION Tudor Cuciureanu1,2, Laura Huiban1,2, Stefan Chiriac1,2.
Presentation transcript:

SPONTANEOUS SEROREVERSION OF ANTI-HEPATITIS C VIRUS DURING THE NATURAL COURSE OF HEPATITIS C VIRUS INFECTION IN THE PATIENTS EVALUATED FOR TREATMENT - A SINGLE CENTER EXPERIENCE Camelia Cojocariu1,2, Laura Huiban1,2, Carol Stanciu2, Cristina-Maria Muzica1,2, Oana Stoica1,2, Irina Girleanu1,2, Ana-Maria Singeap1,2, Tudor Cuciureanu1,2, Stefan Chiriac1,2, Anca Trifan1,2 1 “Grigore T. Popa “ University of Medicine and Pharmacy 2 Institute of Gastroenterology and Hepatology, Iasi, Romania INTRODUCTION: Hepatitis C virus (HCV) infection is common worldwide but there are different prevalence rates in different countries. Spontaneous viral clearance occurs in 10– 25% of infected individuals after acute infection yet controversy exists regarding the frequency of spontaneous clearance during the natural course of HCV infection in the general population. AIM: In our study we aimed to evaluate undetectable ARN HCV prevalence in antibodies HCV population evaluated for IFN free treatment. MATERIAL AND METHODS: We performed a prospective study in which we included all patients with positive anti -HCV antibodies who were admitted in a tertiary referral center from North-Eastern Romania and were evaluated for IFN free treatment between June 1st 2018 and March 1st 2019. All patients included in the study performed the quantitative determination of HCV viraemia. The patients with sustained virological response to interferon (IFN) therapy were excluded from the study. RESULTS: The study included 473 persons with positive anti -HCV antibodies; mean age was 54.6±5.2 years, predominantly female (293- 61.94%). Among all patients with positive anti- HCV antibodies, in 45 (9.51%) cases we found undetectable HCV viraemia. Seroreversion occurred in individuals with a median age of 58 years (range 45–66). Of the patients with undetectable HCV viraemia, 28.8% had elevated transaminases. 473 CONCLUSIONS: The frequency of spontaneous viral clearance in a homogeneous population of immunocompetent subjects not related to treatment with IFN was low (9.51%). These data are consistent with the literature where viral spontaneous clearance was 2-10% in a cohort of HCV infection.